

Citations

1. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.
2. WHO. Radix valerianiae. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:267-276.
3. ESCOP. Valerianae radix. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:539-546.
4. AHP. Valerian root. In: Upton R, ed. American Herbal Pharmacopoeia. Scotts Valley, Calif; 1999.
5. Houghton PJ. Valerian: The genus Valeriana. Medicinal and Aromatic Plants: Industrial Profiles. 51 vol. Amsterdam: Harwood Academic; 1997:505-512.
6. Houghton PJ. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 1999;51:505-512.
7. Morazzoni P, Bombardelli E. Valeriana officinalis: traditional use and recent evaluation of activity. Fitoterapia 1995;66:99-112.
8. McKenna D, Jones K, Hughes K, Humphrey S. Valerian. Botanical Medicines. 2nd ed. Binghamton, NY: Haworth Press; 2002:1007-1037.
9. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 2000;1:91-99.
10. Boyle W. Official Herbs: Botanical Substances in the United States Pharmacopoeias 1820-1990. East Palestine, Ohio: Buckeye Naturopathic Press; 1991.
11. Felter H, Lloyd J. Valeriana. King's American Dispensatory. 2 vol. 1898 Reprint ed. Sandy, Ore: Eclectic Medical Publications, Reprint 1983; 1898:2041-2043.
12. Mills S, Bone K. Principles and Practice of Phytotherapy. Edinburgh: Churchill Livingstone; 2000.
13. Brinker F. Herb Contraindications and Drug Interactions. 3rd ed. Sandy, Ore: Eclectic Medical Publications; 2001.
14. Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects. Epilepsy Behav 2001;2:524-532.
15. Eadie MJ. Could valerian have been the first anticonvulsant? Epilepsia 2004;45:1338-1343.
16. Spinella M. The Psychopharmacology of Herbal Medicine. Cambridge, Mass: MIT Press; 2001.
17. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208-216.
18. Abourashed EA, Koetter U, Brattstrom A. In vitro binding experiments with a valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. Phytomedicine 2004;11:633-638.
19. Muller CE, Schumacher B, Brattstrom A et al. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci 2002;71:1939-1949.
20. Schellenberg R, Sauer S, Abourashed EA et al. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. Planta Med 2004;70:594-597.
21. Granger RE, Campbell EL, Johnston GAR. (+)- And (-)-borneol: efficacious positive modulators of GABA action at human recombinant [alpha]1[beta]2[gamma]2L GABAA receptors. Biochem Pharmacol 2005;69:1101-1111.
22. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res Mol Brain Res 2005;138:191-197.
23. Yuan CS, Mehendale S, Xiao Y et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 2004;98:353-358, table of contents.
24. Oliva I, Gonzalez-Trujano ME, Arrieta J et al. Neuropharmacological profile of hydroalcohol extract of Valeriana edulis ssp. procera roots in mice. Phytother Res 2004;18:290-296.
25. Rasmussen P. Phytotherapy for the treatment of drug withdrawal. Eur J Herbal Med 1997;3:11-22.
26. Ernst E. Herbal remedies for anxiety: a systematic review of controlled clinical trials. Phytomedicine 2006;13:205-208.
27. Muller SF, Klement S. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine 2006;13:383-387.
28. Kennedy DO, Little W, Haskell CF, Scholey AB. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory-induced stress. Phytother Res 2006;20:96-102.
29. Morin CM, Koetter U, Bastien C et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005;28:1465-1471.
30. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004;11:98-104.
31. Lefebvre T, Foster BC, Drouin CE et al. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004;7:265-273.

Citations and Reference Literature: Valerian

32. Budzinski JW, Foster BC, Vandenhoeck S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. *Phytomedicine* 2000;7:273-282.
33. Gurley BJ, Gardner SF, Williams DK et al. Effect of goldenseal, black cohosh, kava kava, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes. *Clin Pharmacol Ther* 2005;77:P36.
34. Gurley BJ, Gardner SF, Hubbard MA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther* 2005;77:415-426.
35. Donovan JL, DeVane CL, Chavin KD et al. Multiple night-time doses of valerian (*Valeriana officinalis*) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. *Drug Metab Dispos* 2004;32:1333-1336.
36. Andreatini R, Leite JR. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. *Eur J Pharmacol* 1994;260:233-235.
37. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. *JAMA* 1998;280:1566-1567.
38. Leuschner J, Muller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. *Arzneimittelforschung* 1993;43:638-641.
39. Hendriks H, Bos R, Woerdenbag HJ, Koster AS. Central nervous depressant activity of valerenic acid in the mouse. *Planta Med* 1985;28-31.
40. Hiller K, Zetler G. Neuropharmacological studies on ethanol extracts of *Valeriana officinalis* L.: behavioural and anticonvulsant properties. *Phytother Res* 1996;10:145-151.
41. Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. *Pharmacopsychiatry* 1988;21:447-448.
42. Ugalde M, Reza V, Gonzalez-Trujano ME et al. Isobolographic analysis of the sedative interaction between six central nervous system depressant drugs and *Valeriana edulis* hydroalcoholic extract in mice. *J Pharm Pharmacol* 2005;57:631-639.
43. Berenbaum MC. What is synergy? *Pharmacol Rev* 1989;41:93-141.
44. Tallarida RJ, Raffa RB. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. *Life Sci* 1996;58:PL 23-28.
45. Williamson EM. Interactions between herbal and conventional medicines. *Expert Opin Drug Saf* 2005;4:355-378.